Skip to main content
. Author manuscript; available in PMC: 2014 Aug 8.
Published in final edited form as: Toxicol Appl Pharmacol. 2011 Aug 7;256(2):154–167. doi: 10.1016/j.taap.2011.08.002

Figure 2.

Figure 2

Hepatic (A) TCDD and (B) PCB153 tissue levels per g liver wet weight measured by HRGC-HRMS (Kopec et al. 2010b). PCB153 levels were potentiated following co-administration with TCDD (in MIX) at 24 and 168 h. However no changes in TCDD hepatic levels were detected following co-treatment with PCB153 (in MIX). Results are displayed as mean ± SE for 3 independent replicates. Data were analyzed by ANOVA followed by Tukey’s post hoc test: *p<0.05 vs. time-matched PCB153 levels alone.